Clevudine

Clevudine

Systematic (IUPAC) name
1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
Clinical data
Routes of administration	Oral
Identifiers
CAS Registry Number	69256-17-3 Y
ATC code	J05AF12 [1]
PubChem	CID 73115
ChemSpider	65894 N
UNII	IN51MVP5F1 N
KEGG	D03537 Y
ChEMBL	CHEMBL458875 N
Chemical data
Formula	C10H13FN2O5
Molecular mass	260.219 g/mol
SMILES O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)[C@H]2F)CO
InChI InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1  N Key:GBBJCSTXCAQSSJ-XQXXSGGOSA-N  N
N (what is this?)  (verify)

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings.

It is a nucleoside analog.^[2]

References